Posts
- Beacon 2024 Product Milestones, and a look ahead to 2025.
- Beacon ADC Cited in mAbs Journal
- Beacon ADC Patents: The World’s First Patent Database Developed for Scientists
- Beacon Cited in Nature Reviews Drug Discovery
- Beacon Intelligence Launches Beacon Neuroscience to Accelerate CNS Drug Development
- Beacon Launches Immune Tolerance Dataset
- Beacon Launches Oncology Deals and Companies Data Expansion
- Beacon RNA Cited in Nature, NPJ Genomic Medicine
- Introducing Beacon Oncology: The Most Comprehensive Oncology Drug Development Database.
Pages
Solutions
- Beacon ADC Database
- Beacon Autoimmune Database
- Beacon Bispecific Database
- Beacon Cancer Vaccine Database
- Beacon Cell Therapy Database
- Beacon Checkpoint Database
- Beacon Cytokine
- Beacon DDR Database
- Beacon Gene Therapy Database
- Beacon Microbiome Database
- Beacon Neuroscience Database
- Beacon Oncology Database
- Beacon Oncolytic Viruses Database
- Beacon RNA Database
- Beacon TPD Database
Events
- 10th CAR-TCR Summit Europe
- 15th Clinical Biomarkers & CDx Summit Europe 2025
- 16th World ADC London Summit
- 16th World ADC San Diego Summit
- 3rd Cell Therapy for Autoimmune Disease Summit
- 4th Next Generation Gene Therapy Vectors 2025
- 4th World ADC Asia Summit 2025
- 5th Novel Conjugates Summit
- 6th Cytokine-Based Drug Development Summit 2025
- 6th TPD & Induced Proximity Summit Europe
- 7th Targeted Radiopharmaceuticals Summit
- 8th Neuroimmunology Drug Development Summit 2026
- 8th TPD & Induced Proximity Summit
- 8th Treg-Directed Therapies Summit
- ADC Partnering & Investment Summit
- Neuroscience Innovation Pharma Partnering Summit
- T-Cell Engager for Autoimmune Disease Summit
- The 10th CAR-TCR Summit
- The 16th World Bispecific Summit
- The 5th Annual mRNA Based Therapeutics Summit
Webinars
- AACR 2024: DDR Related Abstracts
- ADC and Immune Checkpoint Combination Therapies
- ADC Fireside Chat – Is a booming landscape a double-edged sword?
- ADC Linker Technology: Advancements & How to Harness Them
- ADCs: New Ways to Achieve Precision Conjugation and Scalable Purification
- Allogeneic Cell Therapy Innovations
- Bispecific Antibodies and Immune Checkpoint Modulators
- Bivalent Degrader Landscape
- Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development
- Cell Therapy Commercial Research Landscape
- Cytokine Based Drug Development Landscape
- Drug Payload Quantification in LNPs with New Scatter-Free Absorption
- From Subtyping to Measuring and Predicting Outcomes, How AI is Changing Rheumatology and Immunology Research
- Inflammatory Bowel Disease Drug Market Trends
- Liquid Biopsy Landscape: CtDNA in Lung Cancer Research
- Microbiome Targeting Therapeutics in Infectious Disease
- Navigating Payload Innovation and Toxicity Trends in ADC Development
- Novel Drug Conjugates and Clinical Success: An In-Depth Analysis of Emerging ADCs
- Optimizing Next Generation Viral Vector Safety
- Pioneering New Treatment Options in Relapsed or Refractory Multiple Myeloma with a New Amanitin-based ADC
- Review of the Induced Proximity Landscape
- STING TLR Landscape Review
- The ADC Landscape
- The Future of Neuroscience Drug Development: Opportunities and Challenges
- The RNA Gene Therapy Landscape
- The Road Ahead for Addressing Autoimmune Indications with T Cell Therapies
- TPD Disease Landscape
- Unlocking the Future of RNA Therapeutics: Delivery System Evolution, Preclinical Insights, and Market Impact
Infographics
- 2025 ESMO Highlights: Trends in Oncology
- AACR 2025: A Spotlight on New Drugs
- ADC Pre-Clinical Development: Where Are We in 2023?
- ADCs in the Oncology Landscape
- ASCO 2023: TPD Landscape Overview
- ASCO 2024: ADC Highlights
- ASCO 2024: Bispecific Highlights
- ASCO 2024: Checkpoint Highlights
- ASCO 2024: Cytokine Highlights
- Checkpoint Targeting Bispecifics
- DDR Combination Therapies
- Exploring Human Papillomavirus
- Exploring The Synergy Of ADC’s And DDRi’s in Cancer Therapy
- Liquid Biopsy Assays For ctDNA Detection
- Lysosomal Storage Diseases – A Comprehensive Overview
- Microbiome Drug Development in Asia
- Microbiome Drug Development Milestones
- Microbiome Therapeutics and Preclinical Models
- Neoantigen Cancer Vaccines
- Next Generation TPD Degraders
- Next-Gen Therapies: Unlocking the Potential of Bispecific ADCs
- T Cell Engagers: Revolutionizing Autoimmune Disease Treatment
- The Adenosine Pathway Clinical Trial Landscape
- The Molecular Glue Landscape
- The mRNA-Based Therapy Landscape
- The Oncology Deals and Companies Landscape
- The Rise of Bispecific Combination Trials
- Unlocking the Potential of mRNA Cancer Vaccines
Landscape Reviews
- ADC 2024 Landscape Review
- ADC H1 2025 Landscape Review
- Autoimmune H1 2025 Landscape Review
- Bispecific 2024 Landscape Review
- Bispecific H1 2025 Landscape Review
- Cancer Vaccine 2024 Landscape Review
- Cell Therapy 2024 Landscape Review
- Cell Therapy H1 2025 Landscape Review
- Checkpoint 2024 Landscape Review
- Cytokine 2024 Landscape Review
- Cytokine H1 2025 Landscape Review
- DDR 2024 Landscape Review
- Gene Therapy 2024 Landscape Review
- Gene Therapy H1 2025 Landscape Review
- Immune Tolerance 2024 Landscape Review
- Microbiome 2024 Landscape Review
- Neuroscience 2025 Landscape Review
- Oncology 2024 Landscape Review
- Oncology H1 2025 Landscape Review
- Oncolytic Viruses 2024 Landscape Review
- RNA 2024 Landscape Review
- RNA H1 2025 Landscape Review
- TPD 2024 Landscape Review
- TPD H1 2025 Landscape Review
Conference Reports
- 10th CAR-TCR Post Conference Presentation
- 16th World ADC San Diego Post Conference Presentation
- AACR 2023: ADC Post-Conference Report
- AACR 2023: Bispecific Post-Conference Report
- AACR 2023: Cancer Vaccine Post-Conference Report
- AACR 2023: Checkpoint Post-Conference Report
- AACR 2023: Cytokine Post-Conference Report
- AACR 2023: Oncolytic Viruses Post-Conference Report
- AACR 2024: DDR Post-Conference Report
- AACR 2024: RNA Post-Conference Report
- AACR 2024: TPD Post-Conference Report
- AACR 2025: ADC Pre-Conference Planner
- AACR 2025: Bispecific Post-Conference Report
- AACR 2025: Cell Therapy Post-Conference Report
- AACR 2025: Cytokine Post-Conference Report
- AACR 2025: RNA Pre-Conference Planner
- AACR 2025: TPD Post-Conference Report
- AACR NCI EORTC: DDR Post-Conference Report
- ACR 2025: Autoimmune Post-Conference Report
- ASCO 2023: ADC Post-Conference Report
- ASCO 2023: Bispecific Post-Conference Report
- ASCO 2023: Cancer Vaccine Post-Conference Report
- ASCO 2023: Cell Therapy Post-Conference Report
- ASCO 2023: Checkpoint Post-Conference Report
- ASCO 2023: Cytokine Post-Conference Report
- ASCO 2023: Oncolytic Viruses Post-Conference Report
- ASCO 2023: TPD Post-Conference Report
- ASCO 2024: Cancer Vaccine Post-Conference Report
- ASCO 2024: DDR Post-Conference Report
- ASCO 2024: Oncolytic Viruses Post-Conference Report
- ASCO 2024: TPD Post-Conference Report
- ASCO 2025: Cell Therapy Post-Conference Report
- ASCO 2025: Cytokine Post-Conference Report
- ASCO 2025: TPD Conference Report
- ASGCT 2024: Advanced Therapies Post-Conference Report
- ASGCT 2024: Cell Therapy Post-Conference Report
- ASGCT 2024: Gene Therapy Post-Conference Report
- ASGCT 2025: Cell Therapy Post-Conference Report
- ASGCT 2025: Gene Therapy Post-Conference Report
- ASGCT 2025: RNA Post-Conference Report
- ASH 2023: Cell Therapy Post-Conference Report
- ASH 2023: Gene Therapy Post-Conference Report
- ASH 2024: ADC Post-Conference Report
- ASH 2024: Cell Therapy Post Conference Report
- ASH 2025: Bispecific Pre-Conference Planner
- ASH 2025: Cytokine Pre-Conference Report
- ASH 2025: TPD Pre-Conference Report
- ESMO 2023: Checkpoint Post-Conference Report
- ESMO 2023: Cytokine Post-Conference Report
- ESMO 2023: DDR Post-Conference Report
- EULAR 2024: Immune Tolerance Post-Conference Report
- EULAR 2025: Autoimmune Post-Conference Report
- mRNA Summit 2025: Presentation
- SfN 2025 Pre-Conference Planner
- SITC 2023: Cancer Vaccine Post-Conference Report
- SITC 2023: Cell Therapy Post-Conference Report
- SITC 2023: Oncolytic Viruses Post-Conference Report
- SITC 2023: RNA Post-Conference Report
- SITC 2024: Bispecific Post-Conference Report
- SITC 2025: Bispecific Post-Conference Report
- SITC 2025: Cell Therapy Post-Conference Report
- The Neurological Oligonucleotide Landscape Presentation
Market Reports
- A Spotlight on the TGF-β Cancer Clinical Trial Landscape
- AAVrh74 Platform Technology Designation Report
- Armored Cell Therapies
- Bispecifics in Autoimmune Disorders Report
- Cytokine Innovation in IBD Report
- Cytokine-Armoured Cell Therapies: Overcoming Immunosuppression and Improving Persistence
- Deals & Companies Report: Global Commercial Insights From The Biologics Market
- Degraders for Neurological Diseases
- Delving Deeper into Allergy Drug Development:
- Disease Trends in the Oligonucleotide Space
- Gene Therapies For Neurological Diseases
- Global Commercial Insights From the Bispecific and Multispecific Market
- In Vivo CAR Therapies: Review of a Novel Modality
- Investment Trends in Early Stage BioPharma
- Monoclonal Antibodies (mAbs) Unveiled: A Comprehensive Review of the Landscape in Immune-Mediated Diseases
- Navigating the Complex Landscaspe of Skysona and Hematologic Cancer
- Oncolytic Viruses: Monotherapies vs. Combination Therapy
- PD-L1: An Endless Classic or Passing Fancy?
- Pre-Clinical Cytokine Drug Development: An Analysis of the Latest Data
- Review of RNA Clinical Research
- Strategic Insights for Biopharma Innovation
- T Cell Engager Landscape Report
- The Blood Cancer Landscape Report
- The Breast Cancer Landscape
- The CAR T Therapy In Asia Landscape Report
- The Checkpoint Disease Landscape: Exploring the Top Cancer Indications
- The Colorectal Cancer Landscape
- The Evolving Brain Cancer Landscape
- The KRAS Drug Development Landscape Report
- The Latest Breakthrough in Autoimmune Therapy
- The Multiple Sclerosis Drug Development Landscape Report
- The Oligonucleotide Landscape
- The Power of Precision: Exploring Editing Technologies in Gene Therapy
- The Rise of ADCs and Novel Drug Conjugates in Asia
- The US Market and LBP Development
- TIGIT Axis Therapies and The Cancer Clinical Trial Landscape
- Treg Therapies in Autoimmune Diseases
- Trends and Challenges in Early-Stage Cytokine-Based Drug Development Commercialization
- VEGF PDL-1 Multispecifics Report
Hanson Wade Events
- 10th CAR-TCR Summit
- 10th Liquid Biopsy for Precision Oncology Summit
- 10th Microbiome Movement Summit Europe
- 10th Microbiome Movement USA Summit
- 10th Tumor Models Summit San Francisco
- 11th Innate Killer Summit
- 13th Tumor Models Summit
- 14th Alzheimer’s & Parkinson’s Drug Development Summit
- 15th Clinical Biomarkers & CDx Summit Europe
- 15th World CB & CDx Summit
- 16th World ADC London
- 16th World ADC San Diego Summit
- 16th World Bispecific Summit
- 2nd ADC Partnering & Investment Summit
- 2nd ADC Payload Summit
- 2nd ADC Pharmacokinetics & Clinical Pharmacology Summit
- 2nd Cell & Gene Therapy Pricing & Reimbursement
- 2nd Computational RNA Design & Delivery Summit
- 2nd Peptide-Based Therapeutics Summit
- 2nd Personalized Cancer Vaccine Summit
- 2nd Proteomics-Based Drug Discovery Summit
- 2nd Raw Materials for Cell & Gene Therapy Summit
- 2nd Structure-Based Drug Design Summit
- 2nd Translational Digital Pathology & AI Summit
- 2nd TRP Target Selection & Drug Design Summit
- 2nd TRP Target Selection & Drug Design Summit
- 2nd World Companion Diagnostics & Liquid Biopsy Summit APAC
- 3rd ADC Linker & Conjugation Summit
- 3rd ADC Process Devlopment Summit
- 3rd ADC Toxicity Summit
- 3rd CRISPR-Based Therapy Analytical Development Summit
- 3rd DNA Process Development & Manufacturing Summit
- 3rd Donor Selection & Cell Source Summit
- 3rd Fluid & Imaging Biomarkers in Neuroscience Summit
- 3rd Gene Therapy Potency Assay Summit
- 3rd mRNA Process Development & Manufacturing Europe
- 3rd Peptide-Based Therapeutics Summit
- 3rd Spatial Biology for Drug Development Summit
- 4th ADC Analytical Development Summit
- 4th ADC Analytical Development Summit
- 4th AI-Enabled Spatial Biology & Digital Pathology Summit San Diego
- 4th Circular & SaRNA Therapeutics Summit
- 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery
- 4th In Vivo Cell Engineering & Gene Editing Summit
- 4th Liquid Biopsy for Precision Oncology East Coast
- 4th LNP Formulation & Process Development Summit
- 4th Molecular Glue Drug Development Summit
- 4th MRNA Process Development & CMC Summit
- 4th Oligonucleotide Analytical Development & CMC Summit
- 4th Ophthalmic Drug Delivery Summit
- 4th Precision Medicine in Inflammatory Bowel Disease Summit
- 4th Process Development for Cell Therapies Summit
- 4th Targeted Radiopharmaceuticals Summit
- 4th Viral Vector Process Development & Manufacturing Summit
- 4th World ADC Asia Summit
- 5th Cell & Gene Therapy Patient Engagement Summit
- 5th Inner Ear Disorders Therapeutics Summit
- 5th LNP Formulation & Process Development Summit
- 5th mRNA-Based Therapeutics Summit
- 5th mRNA-Based Therapeutics Summit Europe
- 5th Next Generation Gene Therapy Vectors Summit
- 5th Novel Conjugates Summit
- 5th Oligonucleotides for CNS Summit
- 6th Cytokine-Based Drug Development Summit
- 6th Dry AMD & Geographic Atrophy Therapeutics Summit
- 6th Gene Therapy Analytical Development Europe
- 6th Gene Therapy for Opthalmic Disorders
- 6th Gene Therapy Immunogenicity Summit
- 6th RNA Editing Summit
- 6th TCR-based Therapies
- 6th TPD & Induced Proximity Summit Europe
- 7th Allogeneic Cell Therapies Summit
- 7th Cell Therapy Analytical Development Summit
- 7th CNS Drug Delivery Summit
- 7th Exosome-Based Therapeutic Development Summit
- 7th Gene Therapy Analytical Development Summit
- 7th Gene Therapy Analytical Development Summit Europe
- 7th Glioblastoma Drug Development Summit
- 7th Myeloid-Directed Therapies Summit
- 7th RAS-Targeted Drug Development Summit
- 7th RNAi-Based Therapeutics Summit
- 7th T-Cell Engager Therapeutics Summit
- 7th Targeted Radiopharmaceuticals Summit
- 7th TIL Therapies Summit
- 8th CRISPR AgBio Congress
- 8th International Neoantigen Summit
- 8th Neuroimmunology Drug Development Summit
- 8th RNA-Targeted Drug Discovery & Development Summit
- 8th TPD & Induced Proximity Summit
- 8th Treg-Directed Therapies Summit
- 9th Annual DDR Inhibitors Summit
- 9th Antigen-Specific Immune Tolerance Summit
- 9th CAR-TCR Summit Europe
- 9th Complement-Based Drug Development Summit
- 9th Gene Therapy Development Summit
- Dark Genome Target Discovery & Development Summit
- Immune Resetting: B-Cell Mediated & Beyond Summit
- Oligonucleotide-based Therapeutics Summit
- T-Cell Engager for Autoimmune Disease Summit
- T-Cell Engager Therapeutics Summit Europe
- Targeted Therapies Partnering & Licensing Summit Asia
- Tumour Models Summit Nordics
- Tumour Models Summit Nordics
APIs
Data
Market Research
Blogs
Demo Requests
- Request a Beacon ADC Demonstration
- Request a Beacon Autoimmune Demonstration
- Request a Beacon Bispecific Demonstration
- Request a Beacon Cancer Vaccine Demonstration
- Request a Beacon Cell Therapy Demonstration
- Request a Beacon Checkpoint Demonstration
- Request a Beacon Cytokine Demonstration
- Request a Beacon DDR Demonstration
- Request a Beacon Gene Therapy Demonstration
- Request a Beacon Microbiome Demonstration
- Request a Beacon Neuroscience Demonstration
- Request a Beacon Oncology Demonstration
- Request a Beacon Oncolytic Viruses Demonstration
- Request a Beacon RNA Demonstration
- Request a Beacon TPD Demonstration
- Request a Demonstration
- News
Categories
Search